ArticleInfection2018
Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections.
Article in Infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population-Based Study of Patients With B-Cell Malignancies.European journal of haematology · 2026Article
- Evaluation of bloodstream infections in febrile neutropenic patients with hematological malignancy: a retrospective cohort study.BMC infectious diseases · 2026Article
- Predictors and outcomes of recurrent bloodstream infection in hematological malignancies: a multicenter real-world study.Frontiers in cellular and infection microbiology · 2026Observational
- Who is at risk? Clinical features and a predictive model for 30-day mortality in hematologic patients with enterococcal bloodstream infection.Frontiers in cellular and infection microbiology · 2026Article
- Construction and assessment of a predictive framework for Enterobacterales bloodstream infection in real-world adult onco-hematology patients using Lasso-Cox regression.Antimicrobial agents and chemotherapy · 2025Article
- Development and validation of a nomogram for predicting PICC catheter-related bloodstream infection among patients with hematologic malignancies.BMC infectious diseases · 2025Article
- Gram-negative bacterial bloodstream infections in cancer patients: a study of epidemiological trends and antibiotic susceptibility.Tropical medicine and health · 2025Article
- Machine learning-based prognostic model for bloodstream infections in hematological malignancies using Th1/Th2 cytokines.BMC infectious diseases · 2025Article
- Adult acute leukemia patients with gram-negative bacteria bloodstream infection: Risk factors and outcomes of antibiotic-resistant bacteria.Annals of hematology · 2024Article
- Diagnostic value of procalcitonin in infections in patients with malignant hematologic diseases.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Clinical Predictors of Bacteremia Outcome After Initial Empirical Antimicrobial Therapy in Patients with Hematological Malignancies: A Retrospective Analysis.Infection and drug resistance · 2024Article
- Pathogenic spectrum and drug resistance of bloodstream infection in patients with acute myeloid leukaemia: a single centre retrospective study.Frontiers in cellular and infection microbiology · 2024Article
- Article
- Assessing Clinical Outcomes of Vancomycin Treatment in Adult Patients with Vancomycin-SusceptibleAntibiotics (Basel, Switzerland) · 2023Article
- Microbiology and prognostic prediction model of bloodstream infection in patients with hematological malignancies.Frontiers in cellular and infection microbiology · 2023Article
- The Threat of Carbapenem-Resistant Gram-Negative Bacteria in Patients with Hematological Malignancies: Unignorable Respiratory Non-Fermentative Bacteria-Derived Bloodstream Infections.Infection and drug resistance · 2022Article
- A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy.Journal of Cancer · 2021Article
- Gram-Negative Bacteria Bloodstream Infections in Patients with Hematological Malignancies - The Impact of Pathogen Type and Patterns of Antibiotic Resistance: A Retrospective Cohort Study.Infection and drug resistance · 2021Article
- A retrospective study on Escherichia coli bacteremia in immunocompromised patients: Microbiological features, clinical characteristics, and risk factors for shock and death.Journal of clinical laboratory analysis · 2020Article
- Inappropriate initial antimicrobial therapy for hematological malignancies patients with Gram-negative bloodstream infections.Infection · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
purposePatients with hematological malignancies (HMs) are at a higher risk for bloodstream infections (BSIs), which pose significant burden on morbidity and mortality. Better risk stratification helps in medical decision making, increasing efficiency and reducing economic burden. The aim of this study was to develop and validate a reliable prediction model which can be used to identify HM patients at higher risk for BSIs.
methodsWe conducted a retrospective cohort study in three university-affiliated hospitals in Hunan Province, China, from January 2010 to April 2015. A total of 521 HMs patients with BSIs were finally included in this study and were divided into the derivation set and validation set. Survivors and non-survivors were compared to identify the predictors of 30-day mortality.
resultsThe multivariate analysis yielded the following significant mortality-related risk factors: age > 60 years (95% CI 1.047-5.474), relapsed or uncontrolled malignancy (95% CI 2.043-14.029), Pitt bacteremia score > 3 (95% CI 1.614-6.35), prolonged neutropenia (95% CI 1.181-5.824), use of vasopressors (95% CI 3.009-12.210), acute respiratory failure (95% CI 3.061-14.911), fungemia (95% CI 1.334-12.121), inadequate antibiotic treatment (95% CI 1.682-7.591), albumin < 30 g/L (95% CI 1.030-3.446), TBil > 34.2 µmol/L (95% CI 1.109-5.438). In both derivation and validation sets, our model showed reliable prediction value with areas under the receiver operating curve of 0.876 and 0.873.
conclusionsThe risk factors in this study have the ability to identify patients with HMs and BSIs at high risk for mortality. Our model provides an excellent foundation for predicting 30-day morality in HM patients suffering from BSI and helps target high-risk patients for management decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.